Phase 3 Trial Results of Boan Biotech’s BA1102 (Denosumab Injection) Published in Journal of Bone Oncology

The Phase 3 trial results of Boan Biotech’s anti-tumor denosumab injection (Chinese trade name: Boluojia, code-named BA1102, and formerly code-named LY01011) were recently published in Journal o...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025

FINANCE LEASE AGREEMENT

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024

Boan published a review of potential solid tumor target CD228

On December 15, 2024, a comprehensive review article written by Boan Biotech titled "Unlocking the potential of melanotransferrin (CD228): implications for targeted drug development and novel the...

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024

Boan Reached a Strategic Cooperation for Denosumab in Brazil

Boan Biotech announced that it has signed a licensing agreement for commercializing its self-developed Denosumab Injection (BA6101 and BA1102) in the Brazilian market with a strategic partner.Under th...

First Patient Dosed in Phase 1 Study of Boan’s CD228 ADC

Boan Biotech announced that the first patient has been dosed in the Phase 1 clinical trial of BA1302, a novel CD228-directed antibody drug conjugate (ADC), which is the only CD228 ADC undergoing clini...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024